13F Holdings
中文EN

GNLX GENELUX Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1231457 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-95.3%
TTM net income YoY-5.6%
TTM EPS YoY18.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-396,200.0%
Net margin-373,362.5%
FCF margin-270,112.5%
EBITDA margin-393,262.5%

Returns

ROE-130.6%
ROA-95.4%
ROIC (approx.)-180.4%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets24.3%
Debt / equity0.00x
Current ratio4.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue4,762.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue$8,000$8,000$170,000$11.07M
R&D expense$19.85M$19.00M$12.77M$9.08M
SG&A expense$13.37M$12.71M$11.57M$5.00M
Operating income-$33.21M-$31.70M-$24.16M-$3.01M
Interest expense——$173,000—
Income tax———$1.10M
Net income-$32.15M-$29.87M-$28.30M-$5.21M
EBITDA-$32.97M-$31.46M-$23.67M-$2.46M
EPS (basic)-0.86-0.95-1.16-0.57
EPS (diluted)-0.86-0.95-1.16-0.57
Weighted avg. shares (diluted)37.18M31.45M24.43M9.12M
Balance sheet
Cash & equivalents$5.33M$8.56M$9.42M$397,000
Short-term investments—$22.33M$13.77M—
Current assets$15.13M$31.55M$24.20M$1.89M
PP&E, net$2.17M$1.32M$1.17M$644,000
Total assets$19.03M$34.72M$27.89M$5.53M
Current liabilities$6.22M$6.90M$6.55M$31.63M
Short-term debt——$900,000—
Total liabilities$7.48M$8.44M$8.42M$41.31M
Shareholders' equity$11.54M$26.27M$19.47M-$35.78M
Shares outstanding38.14M34.73M26.79M9.13M
Cash flow statement
Operating cash flow-$25.27M-$21.23M-$20.27M-$3.57M
Capital expenditure$1.10M$381,000$1.02M$49,000
Free cash flow-$26.37M-$21.61M-$21.30M-$3.62M
Investing cash flow$12.14M-$8.13M-$14.72M-$49,000
Financing cash flow$9.89M$28.51M$44.02M-$478,000
Depreciation & amortization$244,000$235,000$499,000$553,000
Stock-based compensation$5.87M$5.74M$2.52M$2.42M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.